Physician profile
Jeffrey Rossi
NPI 1306080973
$3,366.89
in general payments reported to CMS, 2019-2025
38 companies · $133 in 2025
The $133 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $333 · 2021: $610 · 2022: $1,052 · 2023: $544 · 2024: $120 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $556.31 | 2022-2025 | Cardiomems, Freestyle Libre 3, Mitraclip |
| Horizon Therapeutics Plc | $449.64 | 2019-2023 | Krystexxa, Tepezza |
| Amgen INC. | $342.29 | 2019-2022 | |
| Novo Nordisk INC | $259.44 | 2019-2024 | Ozempic, Rybelsus |
| Abiomed | $220.86 | 2021 | |
| Lilly USA, LLC | $201.78 | 2020-2023 | Jardiance |
| Vifor Pharma, INC. | $133.38 | 2021-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $121.38 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $98.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.62 | 2020-2023 | Jardiance |
| Tosoh Bioscience, INC. | $91.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $77.54 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $75.33 | 2020-2024 | |
| Calliditas Therapeutics US INC. | $71.70 | 2022-2024 | Tarpeyo |
| Corcept Therapeutics | $68.32 | 2021-2023 | Korlym |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.